You are here

  • Home
  • Archive
  • Volume 29, Issue Suppl 3
  • 312 Aries: a phase 2, open-label study to evaluate rucaparib (PARP inhibitor) in combination with nivolumab (Anti-PD-1 Antibody) in patients with ovarian or urothelial cancer (UC)

Citation Tools

Article menu

Download PDFPDF

E-Poster viewings
Ovarian Cancer
IGCS19-0435
312 Aries: a phase 2, open-label study to evaluate rucaparib (PARP inhibitor) in combination with nivolumab (Anti-PD-1 Antibody) in patients with ovarian or urothelial cancer (UC)
Free

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Moore K, Redhead K, Goble S, et al
312 Aries: a phase 2, open-label study to evaluate rucaparib (PARP inhibitor) in combination with nivolumab (Anti-PD-1 Antibody) in patients with ovarian or urothelial cancer (UC)
International Journal of Gynecologic Cancer 2019;29:A130.